Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

NasdaqGS:AZTA 1 Year Share Price vs Fair Value
NasdaqGS:AZTA 1 Year Share Price vs Fair Value
Explore Azenta's Fair Values from the Community and select yours

It's been a sad week for Azenta, Inc. (NASDAQ:AZTA), who've watched their investment drop 15% to US$28.40 in the week since the company reported its third-quarter result. Revenues were US$144m, with Azenta reporting some 3.9% below analyst expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

earnings-and-revenue-growth
NasdaqGS:AZTA Earnings and Revenue Growth August 7th 2025

Following the recent earnings report, the consensus from seven analysts covering Azenta is for revenues of US$619.0m in 2026. This implies a discernible 7.5% decline in revenue compared to the last 12 months. Per-share statutory losses are expected to explode, reaching US$0.01 per share. Before this earnings report, the analysts had been forecasting revenues of US$628.2m and earnings per share (EPS) of US$0.28 in 2026. While the analysts have made no real change to their revenue estimates, we can see that the consensus is now modelling a loss next year - a clear dip in sentiment compared to the previous outlook of a profit.

See our latest analysis for Azenta

As a result, there was no major change to the consensus price target of US$33.00, with the analysts implicitly confirming that the business looks to be performing in line with expectations, despite higher forecast losses. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Azenta analyst has a price target of US$40.00 per share, while the most pessimistic values it at US$30.00. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Azenta shareholders.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that revenue is expected to reverse, with a forecast 6.0% annualised decline to the end of 2026. That is a notable change from historical growth of 11% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 6.0% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Azenta is expected to lag the wider industry.

Advertisement

The Bottom Line

The biggest low-light for us was that the forecasts for Azenta dropped from profits to a loss next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Azenta's revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Azenta going out to 2027, and you can see them free on our platform here..

We also provide an overview of the Azenta Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NasdaqGS:AZTA

Azenta

Provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.

Flawless balance sheet and undervalued.

Advertisement

Weekly Picks

LO
Lou_Basenese
CUE logo
Lou_Basenese on Cue Biopharma ·

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Fair Value:US$7057.7% undervalued
11 users have followed this narrative
0 users have commented on this narrative
4 users have liked this narrative
HE
HedgeY
ASTS logo
HedgeY on AST SpaceMobile ·

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets

Fair Value:US$17036.9% undervalued
33 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative
FU
ONTO logo
FundamentalFlow on Onto Innovation ·

Onto Innovation: The Advanced Packaging Chokepoint 51.3% undervalued intrinsic discount

Fair Value:US$38027.7% undervalued
23 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7446.7% undervalued
56 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative

Updated Narratives

IM
Imthetxarbi
CBAV logo
Imthetxarbi on Clínica Baviera ·

Baviera: A 40% ROCE Compounding Machine Trading at Distressed Multiples — Fair Value €88/share

Fair Value:€90.7236.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
TR
tripledub
LULU logo
tripledub on lululemon athletica ·

Lululemon Got Boring Right About the Time It Got Cheap. That's Usually the Point

Fair Value:US$15016.7% undervalued
28 users have followed this narrative
6 users have commented on this narrative
0 users have liked this narrative
CA
Cashflow_Queen
RR. logo
Cashflow_Queen on Rolls-Royce Holdings ·

A company I wrote off that quietly turned itself around

Fair Value:UK£14.019.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9721.8% undervalued
56 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7446.7% undervalued
56 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1932.0% undervalued
47 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative